Carbamazepine treatment recovered low N-acetylaspartate+N-acetylaspartylglutamate (tNAA) levels in the megencephaly mouse BALB/cByJ-Kv1.1mceph/mceph

Neurobiology of Disease

Volumn 26, Issue 1, 2007, Pages 221-228

  Westman, Eric ^a   Spenger, Christian ^a   Wahlund, Lars Olof ^a   Lavebratt, Catharina ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Carbamazepine; Epilepsy; LCModel; mceph mceph; MRS; PLS DA

Indexed keywords

CARBAMAZEPINE; CHOLINE; GLUTAMIC ACID; GLUTAMINE; INOSITOL; N ACETYLASPARTIC ACID; N ACETYLASPARTYLGLUTAMIC ACID; POTASSIUM CHANNEL KV1.1; TAURINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN GROWTH; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; FEMALE; GENE; HIPPOCAMPUS; KV1.1 GENE; MACROCEPHALY; MALE; MOUSE; MULTIVARIATE ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; QUANTITATIVE ANALYSIS; SEIZURE;

AMINO ACIDS; ANESTHESIA; ANIMALS; ASPARTIC ACID; BRAIN; CARBAMAZEPINE; CHOLINE; DATA INTERPRETATION, STATISTICAL; DIPEPTIDES; FEMALE; KV1.1 POTASSIUM CHANNEL; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; SEX CHARACTERISTICS;

EID: 33947250076     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2006.12.012     Document Type: Article

References (30)

1. Almgren, M., Persson, A.S., Witgen, B.M., Schalling, M., Nyengaard, J., Lavebratt, C., in press. Lack of potassium channel induces neurogenesis and survival causing 2-fold hippocampal enlargement. Hippocampus.
2. Bertollini R., Kallen B., Mastroiacovo P., and Robert E. Anticonvulsant drugs in monotherapy. Effect on the fetus. Eur. J. Epidemiol. 3 (1987) 164-171
3. Chernov M.F., Kubo O., Hayashi M., Izawa M., Maruyama T., Usukura M., Ono Y., Hori T., and Takakura K. Proton MRS of the peritumoral brain. J. Neurol. Sci. 228 (2005) 137-142
4. Connelly A., Jackson G.D., Duncan J.S., King M.D., and Gadian D.G. Magnetic resonance spectroscopy in temporal lobe epilepsy. Neurology 44 (1994) 1411-1417
5. Demougeot C., Marie C., Giroud M., and Beley A. N-acetylaspartate: a literature review of animal research on brain ischaemia. J. Neurochem. 90 (2004) 776-783
6. Diez M., Schweinhardt P., Petersson S., Wang F.H., Lavebratt C., Schalling M., Hokfelt T., and Spenger C. MRI and in situ hybridization reveal early disturbances in brain size and gene expression in the megencephalic (mceph/mceph) mouse. Eur. J. Neurosci. 18 (2003) 3218-3230
7. Donahue L.R., Cook S.A., Johnson K.R., Bronson R.T., and Davisson M.T. Megencephaly: a new mouse mutation on chromosome 6 that causes hypertrophy of the brain. Mamm. Genome 7 (1996) 871-876
8. Flugel D., McLean M.A., Simister R.J., and Duncan J.S. Magnetisation transfer ratio of choline is reduced following epileptic seizures. NMR Biomed. 19 (2006) 217-222
9. Govindaraju V., Young K., and Maudsley A.A. Proton NMR chemical shifts and coupling constants for brain metabolites. NMR Biomed. 13 (2000) 129-153
10. Groeschel S., Brockmann K., Dechent P., Wilichowski E., Frahm J., and Hanefeld F. Magnetic resonance imaging and proton magnetic resonance spectroscopy of megalencephaly and dilated Virchow-Robin spaces. Pediatr. Neurol. 34 (2006) 35-40
11. Lavebratt C., Trifunovski A., Persson A.S., Wang F.H., Klason T., Ohman I., Josephsson A., Olson L., Spenger C., and Schalling M. Carbamazepine protects against megencephaly and abnormal expression of BDNF and Nogo signaling components in the mceph/mceph mouse. Neurobiol. Dis. 24 (2006) 374-383
12. Lee S.K., Kim D.W., Kim K.K., Chung C.K., Song I.C., and Chang K.H. Effect of seizure on hippocampus in mesial temporal lobe epilepsy and neocortical epilepsy: an MRS study. Neuroradiology 47 (2005) 916-923
13. Lopantsev V., Tempel B.L., and Schwartzkroin P.A. Hyperexcitability of CA3 pyramidal cells in mice lacking the potassium channel subunit Kv1.1. Epilepsia 44 (2003) 1506-1512
14. Lorber J., and Priestley B.L. Children with large heads: a practical approach to diagnosis in 557 children, with special reference to 109 children with megalencephaly. Dev. Med. Child Neurol. 23 (1981) 494-504
15. Neale J.H., Bzdega T., and Wroblewska B. N-Acetylaspartylglutamate: the most abundant peptide neurotransmitter in the mammalian central nervous system. J. Neurochem. 75 (2000) 443-452
16. Öberg, J., L.M.J., Andersson, A., Klason, T., Wang, F., Spenger, C., 2006. In vivo brain 1H magnetic resonance spectroscopy of APP/PS1 mice 2.5-9 months of age Alzheimer's and Dementia: The Journal of the Alzheimer's Association 2, S325.
17. Oz G., Tkac I., Charnas L.R., Choi I.Y., Bjoraker K.J., Shapiro E.G., and Gruetter R. Assessment of adrenoleukodystrophy lesions by high field MRS in non-sedated pediatric patients. Neurology 64 (2005) 434-441
18. Petersson S., Sandberg Nordqvist A., Schalling M., and Lavebratt C. The megencephaly mouse has disturbances in the insulin-like growth factor (IGF) system. Brain Res. Mol. Brain Res. 72 (1999) 80-88
19. Petersson S., Lavebratt C., Schalling M., and Hokfelt T. Expression of cholecystokinin, enkephalin, galanin and neuropeptide Y is markedly changed in the brain of the megencephaly mouse. Neuroscience 100 (2000) 297-317
20. Petersson S., Persson A.S., Johansen J.E., Ingvar M., Nilsson J., Klement G., Arhem P., Schalling M., and Lavebratt C. Truncation of the Shaker-like voltage-gated potassium channel, Kv1.1, causes megencephaly. Eur. J. Neurosci. 18 (2003) 3231-3240
21. Provencher S.W. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn. Reson. Med. 30 (1993) 672-679
22. Provencher S.W. Automatic quantitation of localized in vivo 1H spectra with LCModel. NMR Biomed. 14 (2001) 260-264
23. Riederer F., Bittsansky M., Schmidt C., Mlynarik V., Baumgartner C., Moser E., and Serles W. (1)H magnetic resonance spectroscopy at 3 T in cryptogenic and mesial temporal lobe epilepsy. NMR Biomed. 19 5 (2006) 544-553
24. Sawaishi Y., Yano T., Enoki M., and Takada G. Lidocaine-dependent early infantile status epilepticus with highly suppressed EEG. Epilepsia 43 (2002) 201-204
25. Simister R.J., Woermann F.G., McLean M.A., Bartlett P.A., Barker G.J., and Duncan J.S. A short-echo-time proton magnetic resonance spectroscopic imaging study of temporal lobe epilepsy. Epilepsia 43 (2002) 1021-1031
26. Topcu M., Yalnizoglu D., Saatci I., Haliloglu G., Topaloglu H., Senbil N., Onol S., and Coskun T. Effect of topiramate on enlargement of head in Canavan disease: a new option for treatment of megalencephaly. Turk. J. Pediatr. 46 (2004) 67-71
27. Wide K., Winbladh B., Tomson T., and Kallen B. Body dimensions of infants exposed to antiepileptic drugs in utero: observations spanning 25 years. Epilepsia 41 (2000) 854-861
28. Woermann F.G., McLean M.A., Bartlett P.A., Parker G.J., Barker G.J., and Duncan J.S. Short echo time single-voxel 1H magnetic resonance spectroscopy in magnetic resonance imaging-negative temporal lobe epilepsy: different biochemical profile compared with hippocampal sclerosis. Ann. Neurol. 45 (1999) 369-376
29. Volpe J. Neurology of the newborn (2001), W.B. Saunders Company, Philadelphia
30. Zuberi S.M., Eunson L.H., Spauschus A., De Silva R., Tolmie J., Wood N.W., McWilliam R.C., Stephenson J.P., Kullmann D.M., and Hanna M.G. A novel mutation in the human voltage-gated potassium channel gene (Kv1.1) associates with episodic ataxia type 1 and sometimes with partial epilepsy. Brain 122 Pt 5 (1999) 817-825